Long-Term Intravitreal Dexamethasone Treatment in Eyes with Pretreated Chronic Diabetic Macular Edema

Journal of Ocular Pharmacology and Therapeutics

Volumn 33, Issue 8, 2017, Pages 620-628

  Zandi, Souska ^a   Lereuil, Théo ^b   Freiberg, Florentina ^c   Pfau, Maximilian ^c   Pfister, Isabel B ^a,d   Gerhardt, Christin ^a,d   Michels, Stephan ^c,e   Kodjikian, Laurent ^b   Garweg, Justus G ^a,d  

^a Lindenhofspital   (Switzerland)

^b CROIX ROUSSE HOSPITAL   (France)

^c TRIEMLI HOSPITAL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

dexamethasone intravitreal implant; diabetic macular edema; DME; long term treatment; pretreatment

Indexed keywords

AFLIBERCEPT; ANTIGLAUCOMA AGENT; BEVACIZUMAB; DEXAMETHASONE; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIABETIC MACULAR EDEMA; DISEASE DURATION; DRUG EFFECT; FOLLOW UP; HUMAN; INTERVENTION STUDY; LONG TERM CARE; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; REBOUND; RETREATMENT; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; VITRECTOMY; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETIC RETINOPATHY; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; PATHOLOGY; TIME FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85030481325     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2017.0020     Document Type: Article

References (29)

1. Bandello, F., Pognuz, R., Polito, A., Piracchio, A., Menchini, F., and Ambesi, M. Diabetic macular edema: classification, medical and laser therapy. Semin. Ophthalmol. 18: 251-258, 2003.
2. Grover, D., Li, T.J., and Chong, C.C. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst. Rev. 23: CD005656, 2008.
3. Arevalo, J.F. Diabetic macular edema: changing treatment paradigms. Curr. Opin. Ophthalmol. 25:502-507, 2014.
4. Dutra Medeiros, M., Postorino, M., Navarro, R., Garcia-Arumi, J., Mateo, C., and Corostequi, B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 231:141-146, 2014.
5. Schaal, S., Kaplan, H.J., and Tezel, T.H. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 115:2199-2205, 2008.
6. Gasperini, J.L., Fawzi, A.A., Khondkaryan, A., Lam, L., Chong, L.P., Eliott, D., Walsh, A.C., Hwang, J., and Sadda, S.R. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br. J. Ophthalmol. 96:14-20, 2012.
7. Pacella, E., Vestri, A.R., Muscella, R., Carbotti, M.R., Castellucci, M., Coi, L., Turchetti, P., and Pacella, F. Preliminary results of an intravitreal dexamethasone implant (Ozurdex-) in patients with persistent diabetic macular edema. Clin. Ophthalmol. 7:1423-1428, 2013.
8. Guigou, S., Hajjar, C., Parrat, E., Merite, P.Y., Pommier, S., Matonti, F., Prost-Magnin, O., and Meyer, F. Multicenter Ozurdex- assessment for diabetic macular edema: MOZART study. J. Fr. Ophtalmol. 37:480-485, 2014.
9. Lazic, R., Lukic, M., Boras, I., Draca, N., Vlasic, M., Gabric, N., and Tomic, Z. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina. 34:719-724, 2014.
10. Bressler, S.B., Qin, H., Melia, M., Bressler, N.M., Beck, R.W., Chan, C.K., Grover, S., Miller, D.G.; Diabetic Retinopathy Clinical Research Network. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol. 131:1033-1040, 2013.
11. Haller, J.A., Kuppermann, B.D., Blumenkranz, M.S., Williams, G.A., Weinberg, D.V., Chou, C., Whitcup, S.M.; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch. Ophthalmol. 128:289-296, 2010.
12. Gillies, M.C., Lim, L.L., Campain, A., Quin, G.J., Salem, W., Li, J., Goodwin, S., Aroney, C., McAllister, I.L., and Fraser-Bell, S. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX Study. Ophthalmology. 121:2473-2481, 2014.
13. Muthén, L.K., and Muthén, B.O. Mplus User's Guide. 7th ed. Los Angeles, CA: Muthén & Muthén; 1998-2012.
14. Panozzo, G., Gusson, E., Panozzo, G., and Mura, G.D. Dexamethasone intravitreal implant for diabetic macular edema: indications for a PRN regimen of treatment. Eur. J. Ophthalmol. 25:347-351, 2015.
15. Medeiros, M.D., Alkabes, M., Navarro, R., Garcia-Arumi, J., Mateo, C., and Corcostequi, B. Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. J. Ocul. Pharmacol. Ther. 30:709-716, 2014.
16. Sorkin, N., Loewenstein, A., Habot-Wilner, Z., and Goldstein, M. Intravitreal dexamethasone implant in patients with persistent macular edema of variable etiologies. Ophthalmologica. 232:83-91, 2014.
17. Rishi, P., Rishi, E., Kuniyal, L., and Mathur, G. Short-term results of intravitreal dexamethasone implant (OZURDEX( -) in treatment of recalcitrant diabetic macular edema: a case series. Oman J. Ophthalmol. 5:79-82, 2012.
18. Zucchiatti, I., Lattanzio, R., Querques, G., Querques, L., Del Turco, C., Cascavilla, M.L., and Bandello, F. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica. 228:117-122, 2012.
19. Totan, Y., Güler, E., and Güragac, F.B. Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment. Curr. Eye Res. 22:1-7, 2015.
20. Malclès, A., Dot, C., Voirin, N., Agard, E ., Vié, A.L., Bellocq, D., Denis, P., and Kodjikian, L. Real-life study in diabetic macular edema treated with dexamethasone implant: the Reldex Study. Retina. 37:753-760, 2017.
21. Garweg, J.G., Baglivo, E., Freiberg, F.J., Pfau, M., Pfister, I.B., Michels, S., and Zandi, S. Response of postoperative and chronic uveitic cystoid macular edema to a dexamethasone-based intravitreal implant (Ozurdex). J. Ocul. Pharmacol. Ther. 32:442-450, 2016.
22. Boyer, D.S., Faber, D., Gupta, S., Patel, S.S., Tabandeh, H., Li, X.Y., Liu, C.C., Lou, J., Whitcup, S.M.; Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 31:915-923, 2011.
23. Shah, A.R., Xi, M., Abbey, A.M., Yonekawa, Y., Faia, L.J., Hassan, T.S., Ruby, A.J., and Wolfe, J.D. Short-term efficacy of intravitreal dexamethasone implant in vitrectomized eyes with recalcitrant diabetic macular edema and prior anti-VEGF therapy. J. Ophthalmic. Vis. Res. 11: 183-187, 2016.
24. Dang, Y., Mu, Y., Li, L., Mu, Y., Liu, S., Zhang, C., Zhu, Y., and XU, Y. Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients. Drug Des. Devel. Ther. 8:1441-1449, 2014.
25. Sze, A.M., Luk, F.O., Yip, T.P., Lee, G.K., and Chan, C.K. Use of intravitreal dexamethasone implant in patients with cataract and macular edema undergoing phacoemulsification. Eur. J. Ophthalmol. 25:168-172, 2015.
26. Matonti, F., Pommier, S., Meyer, F., Hajjar, C., Merite, P.Y., Parrat, E., Rouhette, H., Rebollo, O., and Guigou, S. Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. Eur. J. Ophthalmol. 26:454-459, 2016.
27. Scaramuzzi, M., Querques, G., Spina, C.L., Lattanzio, R., and Bandello, F. Repeated intravitreal dexamethasone implant (ozurdex) for diabetic macular edema. Retina. 35: 1216-1222, 2015.
28. Gutiérrez-Benitez, L., Millan, E., Arias, L., Garcia, P., Cobos, E., and Caminal, M. Dexamethasone intravitreal implants for diabetic macular edema refractory to ranibizumab monotherapy or combination therapy. Arch. Soc. Esp. Oftalmol. 90:475-480, 2015.
29. Pacella, F., Romano, M.R., Turchetti, P., Tarquini, G., Carnovale, A., Mollicone, A., Mastromatteo, A., and Pacella, E. An eighteen-month follow-up study on the effects of intravitreal dexamethasone implant in diabetic macular edema refractory to anti-VEGF therapy. Int. J. Ophthalmol. 9:1427-1432, 2016.